Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCTL | Q9NXS2 | 5/20 | 0.50 |
| ▸ | QPCT | Q16769 | 11/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.39 |
| ▸ | PRKACA | P17612 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397076 | 0.86 | QPCTL (0.46) | QPCTLQPCTROCK1ROCK2KDM4E | |
| SCHEMBL2396653 | 0.86 | QPCTL (0.58) | QPCTLQPCTROCK1PRKACA | |
| SCHEMBL2396266 | 0.78 | QPCTL (0.46) | QPCTLQPCTROCK1ROCK2KDM4E | |
| SCHEMBL2398225 | 0.77 | QPCT (0.46) | QPCTLQPCTKDM4E | |
| SCHEMBL2397418 | 0.77 | QPCTL (0.57) | QPCTLQPCTROCK1PRKACA | |
| SCHEMBL2397375 | 0.75 | QPCTL (0.85) | QPCTLQPCT | |
| SCHEMBL2399874 | 0.75 | QPCTL (0.46) | QPCTLQPCTKDM4ENPC1PDPK1 | |
| SCHEMBL2395994 | 0.74 | QPCTL (0.49) | QPCTLQPCT | |
| SCHEMBL2096521 | 0.72 | MMP12 (0.55) | QPCTLQPCTALDH1A1MMP12 | |
| SCHEMBL2397156 | 0.70 | QPCT (0.45) | QPCTLQPCTROCK1ROCK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | claimed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | claimed |
| EP-2542549-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2016-05-11 | — | — | EP | disclosed |
| US-9181233-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-11-10 | — | — | US | disclosed |
| EP-2542549-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2013-01-09 | — | — | EP | disclosed |
| US-20110224259-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011107530-A2 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224259-A1 | NOVEL INHIBITORS | QPCT, GLUL, GLS | QPCTL 5/4885QPCT 1/4885ROCK1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.